Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 159 transactions totaling $409.1M, demonstrating a bearish sentiment with -$152.7M in net insider flow. The most recent transaction on Feb 2, 2026 involved a transaction of 154,000 shares valued at $0.
JANX Insider Activity Summary
Who Is Buying JANX Stock?
No significant insider buying has been recorded for JANX in the recent period.
Who Is Selling JANX Stock?
No significant insider selling has been recorded for JANX in the recent period.
Is Janux Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for JANX is bearish with an Insider Alignment Score of 31/100 and a net flow of -$152.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
JANX Frequently Asked Questions
Understanding JANX Insider Activity
Insider trading at Janux Therapeutics, Inc. (JANX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading JANX stock, having executed 159 transactions in the past 90 days. The most active insider is Jay Lichter (Executive), who has made 11 transactions totaling $97.8M.
Related Tools
Track Janux Therapeutics, Inc. Insider Activity
Get notified when executives and directors at JANX file new Form 4 transactions